Nanobiotix S.A. Data evaluating safety and early signals of efficacy including updated local PFS from the completed dose ...

Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of ...

Actinium Pharmaceuticals (ATNM) announced a clinical program comprising of trials studying Actimab-A in combination with either Keytruda – ...

Chronic cutaneous adverse events affected 8% of patients after checkpoint inhibitor therapy in a cohort study, often ...

Comparative studies have previously shown no difference between the effectiveness of frontline pembrolizumab and nivolumab in patients with advanced melanoma 4. Building on the early success of ...

During a live event, Thach-Giao Truong, MD, moderated a discussion on treating a 78-year-old patient with metastatic melanoma ...

Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.

Neoadjuvant nivolumab has demonstrated efficacy in patients with mismatch repair-deficient, surgically resectable endometrial cancer.

Most patients (75%) received ICI therapy for the first time in the inpatient setting. They received pembrolizumab (51%), nivolumab (30%), nivolumab in combination with ipilimumab (9%), and other ICIs ...

The firm will assess whether adding its CD33-targeted radiotherapy Actimab-A to PD-1 inhibitors will benefit patients more than PD-1 inhibitors alone.

CEL-SCI (CVM) announced that a third-party study published on March 6 in JAMA Oncology provided data that support Multikine’s use as a ...